INVESTIGADORES
TORBIDONI Ana vanesa
artículos
Título:
Immune response to racotumomab in a child with relapsed neuroblastoma.
Autor/es:
SAMPOR C, GUTHMANN MD, SCURSONI A, CACCIAVILLANO W, TORBIDONI A, GALLUZZO L, CAMARERO S, LOPEZ J, DE DÁVILA MT, FAINBOIM L, CHANTADA GL.
Revista:
Frontiers in oncology
Editorial:
Lausanne : Frontiers Research Foundation
Referencias:
Año: 2012 p. 195 - 195
ISSN:
2234-943X
Resumen:
Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.
